Mirati Therapeutics said Monday that its KRAS-targeting cancer drug called adagrasib combined with another immunotherapy was well-tolerated by patients with lung cancer — avoiding the serious liver side effects and treatment discontinuations that have stalled similar efforts by Amgen.
The new safety data are a boost to Mirati’s efforts to expand the number of patients with KRAS-mutated lung cancer who might benefit from adagrasib — and help the drug grow into a commercial blockbuster.
In the mid-stage study reported Monday, moderate, or grade 3, increases in two liver enzymes — markers for liver toxicity — were reported in 8% and 9% of the 75 patients with newly diagnosed lung cancer evaluable for safety. The patients were treated with adagrasib plus Keytruda, the checkpoint inhibitor immunotherapy.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect